Description:RecombinantmonoclonalantibodytoSARS-CoVSglycoprotein.ManufacturedusingAbAb’sRecombinantPlatformwithvariableregions(i.e.specificity)fromtheEBVtransformedhumanBcellcloneS124.MadewithAntibodySequenceslicensedfromHumabsBiomedSA.MadewithAntibodySequenceslicensedfromHumabsBiomedSA.
SpeciesandIsotype:HumanIgG1,kappa
CloneNumber:S124
UniProtAccessionNumberofTargetProtein:PublishedApplication(s):ELISA;NTRL
PublishedSpeciesReactivity:SARSVirus
Immunogen:MadebyimmortalizingIgG-expressingBcellsfromrecoveredSARSpatients.
Specificity:SARS-CoV-neutralizinghmAbs,bindstoSARS-CoVSglycoprotein,inhibitingthebindingoftheglycoproteintohumanACE2.
AntibodyFirstPublishedin:RockxB,CortiD,DonaldsonE,SheahanT,StadlerK,LanzavecchiaA,BaricR.AnefficientmethodtomakehumanmonoclonalantibodiesfrommemoryBcells:potentneutralizationofSARScoronaVirus.NatMed.2004Aug;10(8):871-5.Epub2004Jul11PMID:15247913
ProductForm
Purification:ProteinAaffinitypurified
Suppliedin:PBSwithpreservative(0.02%Proclin300)
StorageRecommendation:Storeat4°Cforupto3months.Forlongertermstoragealiquotintosmallvolumesandstoreat-20°C
Concentration:Seeviallabel.
Importantnote–Thisproductisforresearchuseonly.Itisnotintendedforuseintherapeuticordiagnosticproceduresforhumansoranimals.